CTOs on the Move

Oncocyte

www.oncocyte.com

 
Oncocyte’s mission is to provide tests to physicians and patients that provide answers at critical decision points during lung cancer diagnosis.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.oncocyte.com
  • 1010, Atlantic Avenue
    Alameda, CA USA 94501
  • Phone: 949.409.7600

Executives

Name Title Contact Details

Similar Companies

Front Range Biosciences

Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.

MediQuest Therapeutics

MediQuest Therapeutics is a Maple Valley, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ethicon Endo-Surgery

Ethicon Endo-Surgery is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BTI Products

BTI Products is a Bayfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genfit

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently evaluated in pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for nonalcoholic steatohepatitis, or NASH. NASH is considered by regulatory authorities as a medical emergency because of its potentially severe consequences, although often asymptomatic until late stages, and because its prevalence is on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis (PBC), a severe chronic liver disease. As part of GENFIT’s comprehensive approach to clinical management of NASH patients, the Company is also developing a new, non-invasive and easy-to-access blood-based in vitro diagnostic, or IVD, test to identify patients with NASH who may be appropriate candidates for drug therapy. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 170 employees. GENFIT is a public company listed on the Nasdaq Global Select Market and in compartment B of Euronext’s regulated market in Paris.